Evidence map›Paper›PMID 30953025›Full record

ArticleBone marrow transplantation2019

High-resolution HLA phased haplotype frequencies to predict the success of unrelated donor searches and clinical outcome following hematopoietic stem cell transplantation.

Stéphane Buhler, Helen Baldomero, Sylvie Ferrari-Lacraz, José Manuel Nunes, Alicia Sanchez-Mazas, Stravroula Massouridi-Levrat, Dominik Heim, Jörg Halter, Gayathri Nair, Yves Chalandon and 6 more

Erratum issuedAbstract read
In one paragraph

Article in Bone marrow transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Stéphane BuhlerTransplantation Immunology Unit and National Reference Laboratory for Histocompatibility, Department of Diagnostic, Geneva University Hospitals, Geneva, Switzerland. stephane.buhler@hcuge.ch.
Helen BaldomeroDivision of Hematology, Basel University Hospital, Basel, Switzerland.
Sylvie Ferrari-LacrazTransplantation Immunology Unit and National Reference Laboratory for Histocompatibility, Department of Diagnostic, Geneva University Hospitals, Geneva, Switzerland.
José Manuel NunesAnthropology Unit, AGP Laboratory, Department of Genetics and Evolution, University of Geneva, Geneva, Switzerland.
Alicia Sanchez-MazasAnthropology Unit, AGP Laboratory, Department of Genetics and Evolution, University of Geneva, Geneva, Switzerland.
Stravroula Massouridi-LevratDivision of Hematology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.
Dominik HeimDivision of Hematology, Basel University Hospital, Basel, Switzerland.
Jörg HalterDivision of Hematology, Basel University Hospital, Basel, Switzerland.
Gayathri NairDivision of Hematology, University Hospital of Zurich, Zurich, Switzerland.
Yves ChalandonDivision of Hematology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.
Urs SchanzDivision of Hematology, University Hospital of Zurich, Zurich, Switzerland.
Tayfun GüngörDepartment of Stem Cell Transplantation, University Children's Hospital Zurich, Zurich, Switzerland.
Grazia NicolosoSwiss Blood Stem Cells Registry, Swiss Transfusion SRC, Bern, Switzerland.ORCID http://orcid.org/0000-0001-6783-0349
Jean-Marie TiercyTransplantation Immunology Unit and National Reference Laboratory for Histocompatibility, Department of Diagnostic, Geneva University Hospitals, Geneva, Switzerland.
Jakob PasswegDivision of Hematology, Basel University Hospital, Basel, Switzerland.
Jean VillardTransplantation Immunology Unit and National Reference Laboratory for Histocompatibility, Department of Diagnostic, Geneva University Hospitals, Geneva, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HLA matching is a critical factor for successful allogeneic hematopoietic stem cell transplantation. For unrelated donor searches, matching is usually based on high-resolution typing at five HLA loci, looking for a 10/10 match. Some studies have proposed that further matching at the haplotype level could be beneficial for clinical outcome. In this study, we determined the phased haplotypes of 291 patients using family members and segregation analysis. The sum of ranks of the haplotypes carried by patients was used as a surrogate predictor of a successful unrelated donor search. The putative impact of haplotypes was then analyzed in a cohort of 211 recipients transplanted with 10/10 matched unrelated donors. A logistic regression analysis showed a highly significant effect of the haplotypes in the outcome of a search, but we did not find any significant effect on overall survival, graft versus host disease or relapse/progression following HSCT. This study provides useful data for the optimization of unrelated bone marrow donor searches, but does not confirm previous reports that matching at the haplotype level has a clinical impact following HSCT. Due to the extreme polymorphism of HLA genes, further studies are warranted to better understand the many factors at play.

Identifiers

PMID30953025
PMCPMC7198472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.